Graham Capital Management’s AstraZeneca AZN Stock Holding History

Graham Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.13M	Buy	5,983 +4,151	+227%	+$781K	0.02%	456
2026 Q1	$361K	Buy	+1,832	New	+$353K	0.01%	741
2025 Q3	–	Sell	-5,014	Closed	-$701K	–	1250
2025 Q2	$701K	Buy	+5,014	New	+$703K	0.01%	689
2025 Q1	–	Sell	-5,070	Closed	-$664K	–	1288
2024 Q4	$664K	Sell	5,070 -5,129	-50%	-$718K	0.01%	640
2024 Q3	$1.59M	Buy	+10,199	New	+$1.65M	0.03%	345
2023 Q4	–	Sell	-7,939	Closed	-$1.08M	–	1005
2023 Q3	$1.08M	Buy	+7,939	New	+$1.08M	0.03%	339

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Graham Capital Management's AZN Position: Q2 2026 in Review

Graham Capital Management increased its AstraZeneca (AZN) stake by 227% in Q2 2026, buying an estimated $781K and bringing the position to 5,983 shares worth $1.13M. The position accounts for 0.02% of the portfolio, ranked #456.

Graham Capital Management first reported a position in AZN in Q3 2023 and has held it in 6 quarters since. The position peaked at $1.59M in Q3 2024. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Graham Capital Management held 5,983 shares of AstraZeneca worth $1.13M as of Q2 2026.
Graham Capital Management bought 4,151 AstraZeneca shares in Q2 2026, an estimated $781K.
AstraZeneca made up 0.02% of Graham Capital Management's portfolio in Q2 2026, its #456 holding.
Graham Capital Management first reported a position in AstraZeneca in Q3 2023 and has held it in 6 quarters since.
Graham Capital Management's AstraZeneca position peaked at $1.59M in Q3 2024.
1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Graham Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.